导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.73% | 2606/4773 |
| 近一周 | 0.44% | 259/5458 |
| 近一月 | 3.54% | 224/5421 |
| 近一季 | 3.23% | 421/5205 |
| 近半年 | -0.68% | 1591/4920 |
| 近一年 | 2.92% | 2198/4361 |
| 近两年 | 30.57% | 2282/2954 |
| 近三年 | 28.20% | 1142/2253 |
| 成立以来 | 138.39% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.74% 3384/4961 |
-6.05% 3653/5312 |
- - |
- - |
| 2025 | 9.39% 2866/4813 |
-1.80% 2781/3635 |
5.84% 535/4076 |
-1.63% 3963/4524 |
7.01% 322/4813 |
| 2024 | 28.78% 146/3463 |
8.34% 189/2808 |
4.35% 219/3014 |
14.69% 1927/3129 |
-0.69% 1498/3463 |
| 2023 | -0.61% 460/2656 |
3.06% 1273/2280 |
1.25% 227/2385 |
2.73% 220/2515 |
-7.29% 2108/2655 |
| 2022 | -9.19% 169/2207 |
-4.57% 167/1919 |
0.06% 1584/2016 |
-8.59% 212/2113 |
4.03% 601/2208 |
| 2021 | 0.31% 717/1822 |
5.69% 106/1255 |
-3.34% 1241/1330 |
-2.24% 557/1466 |
0.43% 1113/1822 |
| 2020 | 7.81% 861/1250 |
-13.01% 913/1028 |
3.07% 950/1067 |
10.71% 519/1164 |
8.60% 666/1184 |
| 2019 | 26.90% 559/1092 |
19.31% 628/754 |
1.96% 104/804 |
-1.40% 651/850 |
5.79% 673/918 |
| 2018 | -14.40% 97/834 |
- - |
- - |
- - |
-10.24% 182/691 |
| 2017 | 34.77% 39/714 |
- - |
- - |
- - |
- - |
| 2016 | -2.55% 133/605 |
- - |
- - |
- - |
- - |
| 2015 | 3.75% 230/575 |
- - |
- - |
- - |
- - |
| 2014 | 64.38% 25/237 |
- - |
- - |
- - |
- - |
| 2013 | -9.17% 143/186 |
- - |
- - |
- - |
- - |
| 2012 | 13.44% 21/140 |
- - |
- - |
- - |
- - |
| 2011 | -17.72% 19/102 |
- - |
- - |
- - |
- - |
| 2010 | -15.98% 41/58 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 银河沪深300价值指数A VS. 长安沪深300非周期A(740101) |